Management of Dyslipidemia in Patients After Solid Organ Transplantation

References

• Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003; 14(8): 2084–2091.
   PubMed Web of Science ®Google Scholar
• Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report—2007. J Heart Lung Transplant. 2007; 26(8): 769–781.
   PubMed Web of Science ®Google Scholar
• Trulock EP, Christie JD, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant. 2007; 26(8): 782–795.
   Google Scholar
• Gisbert C, Prieto M, Berenguer M, et al. Hyperlipidemia in liver transplant recipients: prevalence and risk factors. Liver Transpl Surg. 1997; 3(4): 416–422.
   PubMedGoogle Scholar
• Ramezani M, Einollahi B, Ahmadzad-Asl M, et al. Hyperlipidemia after renal transplantation and its relation to graft and patient survival. Transplant Proc. 2007; 39(4): 1044–1047.
   Google Scholar
• Chueh SC, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation. 2003; 76(2): 375–382.
   Google Scholar
• Elloso MM, Azrolan N, Sehgal SN, et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant. 2003; 3(5): 562–569.
   Google Scholar
• Roodnat JI, Mulder PG, Zietse R. Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation. 2000; 69(8): 1704–1710.
   Google Scholar
• Wissing KM, Abramowicz D, Breeders N, Vereerstraeten P. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation. 2000 15; 70(3): 464–472.
   Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493): 1267–1278.
   PubMed Web of Science ®Google Scholar
• Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003; 361(9374): 2024–2031.
   PubMed Web of Science ®Google Scholar
• Foundation NK. K/DOQI Clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003; 41(4): S1–S91.
   Google Scholar
• Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant. 2004; 4(suppl 7): 13–53.
   PubMed Web of Science ®Google Scholar
• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19): 2486–2497.
   PubMed Web of Science ®Google Scholar
• Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation—a pilot study. Transplantation. 1996; 61(10): 1469–1474.
   Google Scholar
• Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995; 333(10): 621–627.
   PubMed Web of Science ®Google Scholar
• Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000; 6(12): 1399–1402.
   PubMed Web of Science ®Google Scholar
• Bilchick KC, Henrikson CA, Skojec D, Kasper EK, Blumenthal RS. Treatment of hyperlipidemia in cardiac transplant recipients. Am Heart J. 2004; 148(2): 200–210.
   Google Scholar
• Moro J, Almenar L, Martinez-Dolz L, et al. Ezetimibe in heart transplantation: initial experience. Transplant Proc. 2007; 39(7): 2389–2392.
   Google Scholar
• Kohnle M, Pietruck F, Kribben A, Philipp T, Heemann U, Witzke O. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am J Transplant. 2006; 6(1): 205–208.
   Google Scholar
• Langone AJ, Chuang P. Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. Transplantation. 2006; 81(5): 804–807.
   Google Scholar
• Turk TR, Voropaeva E, Kohnle M, et al. Ezetimibe treatment in hyper-cholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. Nephrol Dial Transplant. 2008; 23(1): 369–373.
   Google Scholar
• Merck/Schering-Plough. Merck/Schering-Plough Pharmaceuticals provides results of the ENHANCE trial, http://www.merck.com/newsroom/press_releases/product/2008_0114.html. Accessed March 4, 2008.
   Google Scholar
• Jensen RA, Lal SM, Diaz-Arias A, James-Kracke M, Van Stone JC, Ross G Jr. Does cholestyramine interfere with cyclosporine absorption? A prospective study in renal transplant patients. Asaio J. 1995; 41(3): M704–M706.
   Google Scholar
• Pflugfelder PW, Huff M, Oskalns R, Rudas L, Kostuk WJ. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial. J Heart Lung Transplant. 1995; 14(4): 613–622.
   Google Scholar
• Lai SM, Hewett JE, Petroski GF, Van Stone JC, Ross G Jr. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial. Am J Kidney Dis. 1995; 25(4): 616–622.
   Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999; 341(6): 410–418.
   PubMed Web of Science ®Google Scholar
• Vergoulas G, Miserlis G, Solonaki F, et al. Combined treatment of hypercholesterolemia of renal transplant allograft recipients with fluvastatin and gemfibrozil. Transpl Int. 2000; (13 Suppl 1): S64–S67.
   Google Scholar
• Breeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant. 2000; 15(12): 1993–1999.
   Google Scholar
• Hottelart C, El Esper N, Rose F, Achard JM, Foumier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002; 92(3): 536–541.
   PubMed Web of Science ®Google Scholar
• Angeles C, Lane BP, Miller F, Nord EP. Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity. Am J Kidney Dis. 2004; 44(3): 543–550.
   Google Scholar
• Tatsioni A, Chung M, Sun Y, et al. Effects of fish oil supplementation on kidney transplantation: a systematic review and meta-analysis of randomized, controlled trials. J Am Soc Nephrol. 2005; 16(8): 2462–2470.
   Google Scholar